Publication
Admission severity of atrial-fibrillation-related acute ischemic stroke in patients under anticoagulation treatment: a systematic review and meta-analysis
| dc.contributor.author | Garcia, Catarina | |
| dc.contributor.author | Silva, Marcelo | |
| dc.contributor.author | Araújo, Mariana | |
| dc.contributor.author | Henriques, Mariana | |
| dc.contributor.author | Margarido, Marta | |
| dc.contributor.author | Vicente, Patrícia | |
| dc.contributor.author | Nzwalo, Hipólito | |
| dc.contributor.author | Macedo, Ana | |
| dc.date.accessioned | 2022-07-14T12:15:15Z | |
| dc.date.available | 2022-07-14T12:15:15Z | |
| dc.date.issued | 2022-06-20 | |
| dc.date.updated | 2022-06-23T12:12:02Z | |
| dc.description.abstract | In non-valvular-associated atrial fibrillation (AF), direct oral anticoagulants (DOAC) are as effective as vitamin K antagonists (VKA) for the prevention of acute ischemic stroke (AIS). DOAC are associated with decreased risk and severity of intracranial hemorrhage. It is unknown if different pre-admission anticoagulants impact the prognosis of AF related AIS (AF-AIS). We sought to analyze the literature to assess the association between pre-admission anticoagulation (VKA or DOAC) and admission severity of AF-AIS. Methods: A Systematic literature search (PubMed and ScienceDirect) between January 2011 to April 2021 was undertaken to identify studies describing the outcome of AF-AIS. Results: A total of 128 articles were identified. Of 9493 patients, 1767 were on DOAC, 919 were on therapeutical VKA, 792 were on non-therapeutical VKA and 6015 were not anticoagulated. In comparison to patients without anticoagulation, patients with therapeutical VKA and under DOAC presented with less severe stroke (MD −1.69; 95% CI [−2.71, −0.66], p = 0.001 and MD −2.96; 95% Cl [−3.75, −2.18], p < 0.00001, respectively). Patients with non-therapeutical VKA presented with more severe stroke (MD 1.28; 95% Cl [0.45, 2.12], p = 0.003). Conclusions: In AF-AIS, patients under therapeutical VKA or DOAC have reduced stroke severity on admission in comparison to patients without any anticoagulation, with higher magnitude of protection for DOAC. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Journal of Clinical Medicine 11 (12): 3563 (2022) | pt_PT |
| dc.identifier.doi | 10.3390/jcm11123563 | pt_PT |
| dc.identifier.eissn | 2077-0383 | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/17997 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | MDPI | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt_PT |
| dc.subject | Ischemic stroke | pt_PT |
| dc.subject | Atrial fibrillation | pt_PT |
| dc.subject | Oral anticoagulation | pt_PT |
| dc.subject | Stroke severity | pt_PT |
| dc.title | Admission severity of atrial-fibrillation-related acute ischemic stroke in patients under anticoagulation treatment: a systematic review and meta-analysis | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 12 | pt_PT |
| oaire.citation.issue | 11 | pt_PT |
| oaire.citation.startPage | 3563 | pt_PT |
| person.familyName | Nzwalo | |
| person.givenName | Hipólito | |
| person.identifier | 337064 | |
| person.identifier.ciencia-id | 2C1F-E4F3-2C79 | |
| person.identifier.orcid | 0000-0002-1502-3534 | |
| person.identifier.rid | AAG-3931-2020 | |
| person.identifier.scopus-author-id | 36057285600 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | 287f7d4e-5ad8-4794-b526-c61d32c00446 | |
| relation.isAuthorOfPublication.latestForDiscovery | 287f7d4e-5ad8-4794-b526-c61d32c00446 |